Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity

Journal of Immunology

Volumn 163, Issue 10, 1999, Pages 5211-5218

  Shimizu, Jun ^a   Yamazaki, Sayuri ^b   Sakaguchi, Shimon ^a,b  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL PROLIFERATION; CYTOKINE RELEASE; HELPER CELL; IMMUNOREGULATION; LEUKAPHERESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; AUTOIMMUNE DISEASES; CELLS, CULTURED; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; RECEPTORS, INTERLEUKIN-2; SARCOMA, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033571105     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Houghton, A. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.
3. Rosenberg, S. A., and D. E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 19:81.
4. Hara, I., Y. Takechi, and A. N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med. 182:1609.
5. Morgan, D. J., H. T. V. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
6. + T cells and their roles in the induction and prevention of autoimmunity. Immunol. Rev. 123:37.
7. Sakaguchi, S., and N. Sakaguchi. 1994. Thymus, T cells and autoimmunity: various causes but a common mechanism of autoimmune disease. In Autoimmunity: Physiology and Disease. A. Coutinho and M. Kazatchkine, eds. Wiley-Liss, New York, p. 203.
8. Sakaguchi, S., K. Fukuma, K. Kuribayashi, and T. Masuda. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T-cell subset. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a T-cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161:72.
9. bright normal T cells for the induction of thyroiditis. J. Immunol. 141:105.
10. Smith, H., Y.-H. Lou, P. Lacy, and K. S. K. Tung. 1992. Tolerance mechanism in experimental ovarian and gastric autoimmune disease. J. Immunol. 149:2212.
11. low subset. J. Exp. Med. 172:1701
12. McKeever, U., J. P. Mordes, D. L. Greiner, M. C. Appel, J. Rozing, E. S. Handler, and A. A. Rossini. 1990. Adoptive transfer of autoimmune diabetes and thyroiditis to athymic rats. Proc. Natl. Acad. Sci. USA 87:7618.
13. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
14. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387.
15. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160: 1212.
16. + naturally anergic and suppressive T cells; induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1169.
17. + anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162:5309.
18. Sakaguchi, S., M. Toda, M. Asano, M. Itoh, S. S. Morse, and N. Sakaguchi. 1996. T-cell mediated maintenance of self-tolerance and its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9:211.
19. Sakaguchi, S., T. Takahashi, and J. Shimizu. 1999. Breaking immunologic tolerance to tumor cells as a novel immunotherapy for cancer. In Cell Therapy. Y. Ikeda, ed. Springer-Verlag Tokyo, Tokyo. In press.
20. Waldmann, T. A. 1991. The interleukin-2 receptor. J. Biol. Chem. 266:2681.
21. + cells. J. Immunol. 126:1393.
22. Jackson, A. L., H. Matsumoto, M. Janszen, V. Maino, A. Blidy, and S. Sheye. 1990. Restricted expression of p55 interleukin 2 receptor (CD25) on human T cells. Clin. Immunol. Immunopathol. 54:126.
23. + T cells expressing IL-2 receptor α-chain (CD25) and having a functionally transient nature into memory cells. Int. Immunol. 3:1349.
24. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 259:1739.
25. Noben-Trauth, N., P. Kropf, and I. Muller. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271:987.
26. Schorle, H., T. Holtschke, T. Hunig, A. Schimpl, and I. Horak. 1991. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352:621.
27. Sendo, F., T. Aoki, E. A. Boyse, and C. K. Buafo. 1975. Natural occurrence of lymphocytes showing cytotoxic activity to BALB/c radiation-induced leukemia RL male 1 cells. J. Natl. Cancer Inst. 55:603.
28. Nakayama, E., H. Shiku, T. Takahashi, H. F. Oettgen, and L. J. Old. 1979. Definition of a unique cell surface antigen of mouse leukemia RL♂ 1 by cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 76:3486.
29. Kuribayashi, K., A. Keyaki, S. Sakaguchi, and T. Masuda. 1985. Effector mechanisms of syngeneic anti-tumor responses in mice. Immunology 56:127.
30. Uenaka, A., T. Ono, T. Akisawa, H. Wada, T. Yasuda, and E. Nakayama. 1994. Identification of a unique antigen peptide pRL1 on BALB/c RL♂ 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the akt oncogene. J. Exp. Med. 180:1599.
31. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, L. Young, M. El-Garnil, S. A. Rosenberg, and J. C. Young. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
32. - T cells have potential to reject antigenically irrelevant (by-stander) tumor cells on activation with the specific target tumor cells. Cancer Immunol. Immunother. 24:8.
33. Ortega-R., G., R. J. Robb, E. M. Shevach, and T. R. Malek. 1984. The murine IL-2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J. Immunol. 133:1970.
34. Ceredig, R., J. W. Lowenthal, M. Nabholz, and R. H. MacDonald. 1985. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 314:98.
35. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120:2027.
36. Hsieh, C. S., S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181:713.
37. Mosier, D .E., K. L. Stell, R. J. Gulizia, B. E. Torbett, and G. L. Gilmore. 1993. Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J. Exp. Med. 177:191.
38. - cells. J. Exp. Med. 179:1957.
39. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
40. Rosenberg, S. A., and M. T. Lotze. 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Anna. Rev. Immunol. 4:681.
41. Yang, J. C., J. J. Mule, and S. A. Rosenberg. 1986. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J. Immunol. 137:715.
42. Phillips, J. H., and L. L. Lanier. 1986. Dissection of the lymphokine-activated killer phenomenon. J. Exp. Med. 164:814.
43. Fujimoto, S., M. I. Greene, and A. H. Schon. 1976. Regulation of the immune response to tumor antigen. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol. 116:791.
44. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 55:1063.
45. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
46. + T cell-mediated immunity. J. Exp. Med. 168:2193.
47. Glimcher, L. H., D. L. Longo, I. Green, and R. H. Schwartz. 1981. Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J. Exp. Med. 154:1652.
48. Lattime, E. C., S. Gillis, G. Pecoraro, and O. Stutman. 1982. Ia-dependent interleukin 2 production in syngeneic cellular interactions. J. Immunol. 128:480.
49. Grimm, E. A., A. Mazumder, H. Z. Zhang, and S. A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823.
50. Sakaguchi, S., and N. Sakaguchi. 1989. Organ-specific autoimmune diseases induced in mice by elimination of T-cell subset. V. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol 142:471.
51. Sakaguchi, S., E. H. Ermak, M. Toda, L. J. Berg, W. Ho, B. Fazekas de St. Groth, P. A. Peterson, N. Sakaguchi, and M. M. Davis. 1994. Induction of autoimmune disease in mice by germline alteration of the T cell receptor gene expression. J. Immunol. 152:1471.
52. Sakaguchi, N., K. Miyai, and S. Sakaguchi. 1994. Ionizing radiation and auto-immunity: induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J. Immunol. 152:2586.
53. + T cells. J. Immunol. 162:5309.
54. Shevach, E. M. 1998. Organ-specific autoimmunity. In Fundamental Immunology, 4th ed. W. E. Paul, ed. Lippincott-Raven, Philadelphia, p. 1089.
55. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
56. Young, J. W., and K. Inaba. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7.
57. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.